argus

Natco Pharma Ltd.

NSE: NATCOPHARMINE987B0102615,101 Cr

Timeline

Time (IST)TypeMEventSrc
26 Aug, 02:46 pmNatco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011bse
25 Aug, 12:22 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
25 Aug, 12:18 pmNatco Pharma Limited has informed the Exchange regarding a press release dated August 25, 2026, titled "Investment in eGenesis, Inc.".nse
21 Aug, 05:27 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
21 Aug, 05:23 pmNatco Pharma Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Conclusion of US FDA Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit".nse
19 Aug, 09:02 amNatco Pharma Limited has informed the Exchange about Investor Presentationnse
19 Aug, 09:00 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
18 Aug, 12:41 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
18 Aug, 12:37 pmNatco Pharma Limited has informed the Exchange about Transcriptnse
16 Aug, 09:06 amNatco Pharma Limited has informed the Exchange about Copy of Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.nse
14 Aug, 06:59 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
14 Aug, 06:55 pmNatco Pharma Limited has informed the Exchange about Link of Recordingnse
14 Aug, 05:39 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
14 Aug, 05:37 pmNatco Pharma Limited has informed the Exchange about Presentationnse
14 Aug, 02:20 pmNatco Pharma Ltd - 524816 - Corporate Action-Board approves Dividendbse
14 Aug, 02:16 pmNatco Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 20-Aug-2026.nse
14 Aug, 02:13 pmNatco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome Of Board Meetingbse
14 Aug, 02:12 pmNatco Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27nse
11 Aug, 05:53 pmNatco Pharma Ltd - 524816 - Update on board meetingbse
06 Aug, 04:50 pmNatco Pharma Ltd - 524816 - Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th June, 2026 And Declare Interim Dividend, If Anybse
18 Jul, 04:49 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Jul, 04:39 pmNatco Pharma Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "NATCO received Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)".nse
14 Jul, 11:54 amThe Company has informed the Exchange regarding a press release dated July 14, 2026, titled "NATCO Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited".nse
14 Jul, 11:49 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
14 Jul, 10:06 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Orderbse
14 Jul, 09:56 amNatco Pharma Limited has informed the Exchange about Action(s) taken or orders passednse
08 Jul, 12:05 pmNatco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026.nse
06 Jul, 05:47 pmWe would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the below mentioned officials of the Company has been designated as follows w.e.f. 6th July, 2026: 1. Mr. Gnanadeva Chalapathy Gudipati has been designated as Senior Vice President - Analytical Research & Development; andMr. Madhava Rao Karicherla has been designated as Vice President Formulation Research & Develnse
06 Jul, 05:38 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Managementbse
30 Jun, 04:18 pmNatco Pharma Limited has informed the Exchange about Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division Kothur of the Company has superannuated today i.e., with effect from the closure of business hours on 30th June, 2026nse
30 Jun, 04:10 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Managementbse
04 Jun, 03:00 pmNatco Pharma Limited has informed the Exchange about Transcriptnse
04 Jun, 02:53 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
03 Jun, 11:15 amNatco Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection".nse
03 Jun, 11:14 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
30 May, 12:24 pmNatco Pharma Limited has informed the Exchange about Copy of Newspaper Publication of Annual Audited Financial Results for the quarter and year ended March 31, 2026nse
30 May, 12:19 pmNatco Pharma Limited has informed the Exchange about Link of Recordingnse
30 May, 12:18 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
29 May, 03:34 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
29 May, 03:30 pmNatco Pharma Limited has informed the Exchange about FY26 Earnings Presentationnse
29 May, 02:28 pmNatco Pharma Ltd - 524816 - Audited Financial Results For The Quarte And Year Ended 31St March, 2026bse
29 May, 02:21 pmNatco Pharma Limited has submitted to the Exchange, the Audited financial results for the quarter and year ended March 31, 2026.nse
26 May, 04:21 pmNatco Pharma Ltd - 524816 - Compliances-Reg.24(A)-Annual Secretarial Compliancebse
18 May, 04:38 pmNatco Pharma Ltd - 524816 - Board Meeting Intimation for Considering Audited Financial Results For The Financial Year Ended 31St March, 2026bse
15 May, 11:47 amNatco Pharma Ltd - 524816 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015bse
14 May, 04:25 pmNatco Pharma Ltd - 524816 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015bse
14 May, 04:17 pmNatco Pharma Limited has informed the Exchange about Action(s) initiated or orders passednse
29 Apr, 05:30 pmNatco Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.nse
24 Mar, 05:30 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Acquisitionbse
24 Mar, 05:22 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Scheme of Arrangementbse